This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates
Scientific Reports Open Access 04 May 2022
-
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
Scientific Reports Open Access 21 February 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chari, R.V., Miller, M.L. & Widdison, W.C. Angew. Chem. 53, 3796–3827 (2014).
Senter, P.D. & Sievers, E.L. Nat. Biotechnol. 30, 631–637 (2012).
Hamblett, K.J. et al. Clin. Cancer Res. 10, 7063–7070 (2004).
Strop, P. et al. Chem. Biol. 20, 161–167 (2013).
Alley, S.C. et al. Bioconjug. Chem. 19, 759–765 (2008).
Shen, B.Q. et al. Nat. Biotechnol. 30, 184–189 (2012).
Acknowledgements
We thank D. McDonough and C. Samain for their help with PK experiments, G. Bolton for technical assistance and T. Kuo and O.-K. Wong for reading the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
All authors are employees of Pfizer, Inc.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8, and Supplementary Tables 1–3, and Supplemental Experimental Procedures (PDF 5728 kb)
Rights and permissions
About this article
Cite this article
Strop, P., Delaria, K., Foletti, D. et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33, 694–696 (2015). https://doi.org/10.1038/nbt.3274
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3274
This article is cited by
-
The target atlas for antibody-drug conjugates across solid cancers
Cancer Gene Therapy (2024)
-
Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates
Scientific Reports (2022)
-
In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies
Cancer Immunology, Immunotherapy (2020)
-
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
Scientific Reports (2019)
-
Computationally designed antibody–drug conjugates self-assembled via affinity ligands
Nature Biomedical Engineering (2019)